Tal Zvi Zaks - May 10, 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Medical Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
May 10, 2021
Transactions value $
-$536,806
Form type
4
Date filed
5/11/2021, 04:12 PM
Next filing
May 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $44.8K +3.67K $12.21* 3.67K May 10, 2021 Direct F1
transaction MRNA Common Stock Sale -$94K -600 -16.35% $156.60 3.07K May 10, 2021 Direct F1, F2
transaction MRNA Common Stock Sale -$155K -985 -32.08% $157.48 2.09K May 10, 2021 Direct F1, F3
transaction MRNA Common Stock Sale -$252K -1.59K -76.02% $158.88 500 May 10, 2021 Direct F1, F4
transaction MRNA Common Stock Sale -$31.9K -200 -40% $159.63 300 May 10, 2021 Direct F1, F5
transaction MRNA Common Stock Sale -$16.2K -100 -33.33% $161.64 200 May 10, 2021 Direct F1
transaction MRNA Common Stock Sale -$32.6K -200 -100% $163.12 0 May 10, 2021 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -3.67K -2.6% $0.00 138K May 10, 2021 Common Stock 3.67K $12.21 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.99 to $156.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.03 to $158.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.28 to $159.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.58 to $159.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.00 to $163.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).